Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker MRK · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025). NCT07722611 · Polycythemia Vera Bomedemstat, Ruxolitinib | MRK Merck Sharp & Dohme LLC | Phase 2/3 | Recruiting | 380 | Jun 25, 2032 | Registry ↗ |
| Nov 13, 2026 | A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) NCT07709000 · Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma MK-1045, Acetaminophen (or similar antipyretic) | MRK Merck Sharp & Dohme LLC | Phase 2 | Recruiting was not yet recruiting | 60 | Nov 16, 2033 | Registry ↗ |
| Nov 13, 2026 | A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) NCT07634471 · Follicular Lymphoma MK-1045, Rituximab | MRK Merck Sharp & Dohme LLC | Phase 2/3 | Recruiting | 960 | Jul 23, 2032 | Registry ↗ |
| Nov 13, 2026 | A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) NCT07519772 · Lymphoma, Non-Hodgkin, Lymphoma, Follicular MK-1045 | MRK Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | 280 | Jul 1, 2030 | Registry ↗ |
| Nov 13, 2026 | A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC… NCT07489495 · Carcinoma, Renal Cell Belzutifan, Zanzalintinib | MRK Merck Sharp & Dohme LLC | Phase 3 | Recruiting | 758 | Nov 27, 2030 | Registry ↗ |
| Nov 13, 2026 | A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) NCT07222488 · Bladder Cancer, Urinary Bladder Neoplasms MK-3120 | MRK Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | 45 | Jul 30, 2027 | Registry ↗ |
| Nov 13, 2026 | A Study of V118E in Healthy Participants (V118E-003) NCT07168915 · Healthy V118E, PREVNAR 20™ | MRK Merck Sharp & Dohme LLC | Phase 1 | Active, not recruiting | 126 | Jul 6, 2027 | Registry ↗ |
| Nov 13, 2026 | A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubici… NCT06890884 · Lymphoma, Large B-Cell, Diffuse Zilovertamab vedotin, Rituximab | MRK Merck Sharp & Dohme LLC | Phase 2 | Recruiting | 594 | Dec 13, 2027 | Registry ↗ |
| Nov 13, 2026 | A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003). NCT06843447 · Ovarian Cancer Recurrent Raludotatug Deruxtecan, Carboplatin | MRK Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | 605 | Mar 27, 2029 | Registry ↗ |
| Nov 13, 2026 | A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (… NCT06818643 · Advanced Solid Tumors, Malignant Neoplasm MK-3120 | MRK Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | 270 | Feb 8, 2028 | Registry ↗ |
| Nov 13, 2026 | Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC… NCT06788912 · Lung Neoplasm Malignant Pembrolizumab (neoadjuvant), Cisplatin | MRK Merck Sharp & Dohme LLC | Phase 2 | Active, not recruiting | 60 | Feb 6, 2032 | Registry ↗ |
| Nov 13, 2026 | Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U0… NCT06780111 · Esophageal Squamous Cell Carcinoma Pembrolizumab, I-DXd | MRK Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | 298 | Jan 4, 2032 | Registry ↗ |
| Nov 13, 2026 | Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Sq… NCT06780098 · Lung Neoplasm R-DXD, I-DXD | MRK Merck Sharp & Dohme LLC | Phase 2 | Recruiting | 144 | Mar 2, 2032 | Registry ↗ |
| Nov 13, 2026 | A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide… NCT06717347 · Diffuse Large B-Cell Lymphoma Zilovertamab vedotin, Rituximab | MRK Merck Sharp & Dohme LLC | Phase 3 | Recruiting | 1,046 | Jul 2, 2029 | Registry ↗ |
| Nov 13, 2026 | Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Pa… NCT06469944 · Gastroesophageal Junction, Gastroesophageal Adenocarcinoma Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT) | MRK Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | 160 | Sep 12, 2029 | Registry ↗ |
| Nov 13, 2026 | Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesos… NCT06353386 · Prostatic Neoplasms, Castration-Resistant Opevesostat, Olaparib | MRK Merck Sharp & Dohme LLC | Phase 1/2 | Active, not recruiting was recruiting | 220 | Jan 15, 2029 | Registry ↗ |
| Nov 13, 2026 | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) NCT06136624 · Prostate Cancer Metastatic Opevesostat, Abiraterone acetate | MRK Merck Sharp & Dohme LLC | Phase 3 | Recruiting | 1,310 | Nov 30, 2028 | Registry ↗ |
| Nov 13, 2026 | Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure D… NCT05714085 · Heart Failure, Left Ventricular Systolic Dysfunction Vericiguat tablet, Vericiguat suspension | MRK Merck Sharp & Dohme LLC | Phase 2/3 | Recruiting | 342 | Aug 20, 2029 | Registry ↗ |
| Nov 13, 2026 | Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inh… NCT05612035 · Pulmonary Hypertension, Chronic Obstructive Pulmonary Disea… Frespaciguat, Placebo | MRK Merck Sharp & Dohme LLC | Phase 2 | Active, not recruiting | 129 | Apr 9, 2026 | Registry ↗ |
| Nov 13, 2026 | Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic… NCT04924075 · Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine T… Belzutifan | MRK Merck Sharp & Dohme LLC | Phase 2 | Recruiting | 355 | Nov 18, 2032 | Registry ↗ |
| Nov 13, 2026 | Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Partici… NCT04895722 · Colorectal Cancer Pembrolizumab, Pembrolizumab/Quavonlimab | MRK Merck Sharp & Dohme LLC | Phase 2 | Completed was active, not recruiting | 302 | May 21, 2025 | Registry ↗ |
| Nov 13, 2026 | Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Current… NCT03486873 · Solid Tumors, Hematologic Malignancies Pembrolizumab, Standard of Care (SOC) | MRK Merck Sharp & Dohme LLC | Phase 3 | Recruiting | 3,500 | Aug 4, 2043 | Registry ↗ |
| Nov 13, 2026 | Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participant… NCT02625961 · Bladder Cancer Pembrolizumab, Pembrolizumab/vibostolimab coformulation | MRK Merck Sharp & Dohme LLC | Phase 2 | Terminated | 296 | Nov 5, 2025 | Registry ↗ |
| Nov 13, 2026 | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lympho… NCT02332668 · Melanoma, Lymphoma Pembrolizumab | MRK Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | 370 | Feb 2, 2028 | Registry ↗ |
| Nov 12, 2026 | A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on… NCT07850609 · HIV Alimatravir | MRK Merck Sharp & Dohme LLC | Phase 2 | Recruiting was not yet recruiting | 80 | Dec 2, 2027 | Registry ↗ |
| Nov 12, 2026 | A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK… NCT07705607 · Diabetic Retinopathy, Macular Edema MK-8748, Aflibercept | MRK Merck Sharp & Dohme LLC | Phase 3 | Recruiting | 1,104 | Nov 30, 2028 | Registry ↗ |
| Nov 12, 2026 | A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK… NCT07705555 · Diabetic Retinopathy, Macular Edema MK-8748, Aflibercept | MRK Merck Sharp & Dohme LLC | Phase 3 | Recruiting | 960 | Oct 31, 2028 | Registry ↗ |
| Nov 12, 2026 | A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021) NCT07661108 · Healthy MK-8527, Probenecid | MRK Merck Sharp & Dohme LLC | Phase 1 | Completed was active, not recruiting | 44 | Oct 28, 2026 | Registry ↗ |
| Nov 12, 2026 | A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004) NCT07614984 · Lipoprotein(a) MK-7262, Enlicitide | MRK Merck Sharp & Dohme LLC | Phase 2 | Recruiting | 750 | Oct 12, 2027 | Registry ↗ |
| Nov 12, 2026 | A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (… NCT07554339 · Non-small Cell Lung Cancer Calderasib, Durvalumab | MRK Merck Sharp & Dohme LLC | Phase 3 | Recruiting | 310 | Dec 15, 2032 | Registry ↗ |
| Nov 12, 2026 | A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Acti… NCT07463183 · Colitis Ulcerative, Ulcerative Colitis MK-8690, Placebo | MRK Merck Sharp & Dohme LLC | Phase 2 | Recruiting | 100 | Oct 28, 2027 | Registry ↗ |
| Nov 12, 2026 | MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-… NCT07431827 · Non-small Cell Lung Cancer Calderasib, MK-3475A | MRK Merck Sharp & Dohme LLC | Phase 3 | Recruiting | 400 | Oct 26, 2039 | Registry ↗ |
| Nov 12, 2026 | A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following A… NCT07227402 · Renal Cell Carcinoma Belzutifan, Zanzalintinib | MRK Merck Sharp & Dohme LLC | Phase 3 | Recruiting | 904 | Feb 27, 2032 | Registry ↗ |
| Nov 12, 2026 | A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamo… NCT07221474 · Squamous Non-small Cell Lung Cancer Intismeran Autogene, Pembrolizumab | MRK Merck Sharp & Dohme LLC | Phase 2 | Recruiting | 180 | Jul 2, 2029 | Registry ↗ |
| Nov 12, 2026 | A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell… NCT07190248 · Non-small Cell Lung Cancer Calderasib, Pembrolizumab (+) Berahyaluronidase alfa | MRK Merck Sharp & Dohme LLC | Phase 3 | Recruiting | 675 | Dec 7, 2029 | Registry ↗ |
| Nov 12, 2026 | A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-0… NCT07133633 · Radiographic Axial Spondyloarthritis Tulisokibart, Placebo | MRK Merck Sharp & Dohme LLC | Phase 2 | Active, not recruiting was recruiting | 315 | Mar 29, 2027 | Registry ↗ |
| Nov 12, 2026 | A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With… NCT07058077 · Heterozygous Familial Hypercholesterolemia (HeFH) Enlicitide Decanoate, Placebo | MRK Merck Sharp & Dohme LLC | Phase 2/3 | Recruiting | 153 | Dec 4, 2033 | Registry ↗ |
| Nov 12, 2026 | A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colo… NCT06997497 · Colon Adenocarcinoma, Rectal Adenocarcinoma Calderasib, Oxaliplatin | MRK Merck Sharp & Dohme LLC | Phase 3 | Recruiting | 477 | Mar 28, 2029 | Registry ↗ |
| Nov 12, 2026 | Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With… NCT06797635 · Breast Neoplasms, Breast Cancer Patritumab deruxtecan, Pembrolizumab | MRK Merck Sharp & Dohme LLC | Phase 2 | Recruiting | 372 | Dec 31, 2029 | Registry ↗ |
| Nov 12, 2026 | A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004) NCT06688058 · Healthy V540D, GARDASIL®9 | MRK Merck Sharp & Dohme LLC | Phase 1 | Active, not recruiting | 72 | Jan 29, 2027 | Registry ↗ |
| Nov 12, 2026 | A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant… NCT06345729 · Non-small Cell Lung Cancer Calderasib, Placebo | MRK Merck Sharp & Dohme LLC | Phase 3 | Recruiting | 348 | Jan 24, 2028 | Registry ↗ |
| Nov 10, 2026 | A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With… NCT07743164 · Ovarian Cancer, Peritoneal Cancer R-DXd, Bevacizumab | MRK Merck Sharp & Dohme LLC | Phase 3 | Recruiting | 646 | Aug 31, 2031 | Registry ↗ |
| Nov 10, 2026 | A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01) NCT07700758 · Malignant Neoplasm Belzutifan | MRK Merck Sharp & Dohme LLC | Phase 2 | Recruiting | 15 | Jan 2, 2034 | Registry ↗ |
| Nov 10, 2026 | A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019) NCT07595263 · Healthy Ulonivirine, Methadone | MRK Merck Sharp & Dohme LLC | Phase 1 | Completed was recruiting | 14 | Sep 29, 2026 | Registry ↗ |
| Nov 10, 2026 | A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) NCT07570173 · B-cell Acute Lymphoblastic Leukemia MK-1045, Blinatumomab | MRK Merck Sharp & Dohme LLC | Phase 2/3 | Recruiting | 340 | Oct 18, 2033 | Registry ↗ |
| Nov 10, 2026 | A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-… NCT07419295 · Bladder Cancer Sacituzumab tirumotecan, Vinflunine | MRK Merck Sharp & Dohme LLC | Phase 3 | Recruiting | 590 | Jul 27, 2029 | Registry ↗ |
| Nov 10, 2026 | A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) NCT07405151 · Oesophageal Squamous Cell Carcinoma I-DXd, Rescue Medication | MRK Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | 60 | Jun 12, 2027 | Registry ↗ |
| Nov 10, 2026 | A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) NCT07318558 · Ovarian Neoplasms, Ovarian Cancer Sacituzumab tirumotecan, Bevacizumab | MRK Merck Sharp & Dohme LLC | Phase 3 | Recruiting | 900 | Feb 25, 2033 | Registry ↗ |
| Nov 10, 2026 | KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cel… NCT07252739 · Malignant Neoplasm MK-1084, Pembrolizumab | MRK Merck Sharp & Dohme LLC | Phase 2 | Recruiting | 140 | Nov 15, 2029 | Registry ↗ |
| Nov 10, 2026 | A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBI… NCT07013487 · Healthy V181, Placebo | MRK Merck Sharp & Dohme LLC | Phase 3 | Active, not recruiting | 12,000 | Sep 6, 2031 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:13 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances